| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16c3929442960d940ef1e6aa830b57c9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate |
2017-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf1bc55523b0588ff460a7f466618ec6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75c0fb044077f5ed2813d2db91c6793b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9010aa4c93007db7bf9b0f314c11ff7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5917e04fb095a44dca3a962998ef06c5 |
| publicationDate |
2018-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3411033-A1 |
| titleOfInvention |
Fostemsavir for use in heavily treatment-experienced hiv-1 infected individuals |
| abstract |
A method of attaining virologic suppression in a heavily treatment-experinced (HTE) individual infected with the HIV-1 virus involves administering to the individual a treatment regimen comprising the drug fostemsavir together with an optimized background therapy (OBT). This treatment regimen should maintain virologic suppression to a plasma HIV-1 RNA level of less than 200 copies (c)/mL for an extended period. |
| priorityDate |
2016-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |